GENB AS Stock Other OTC
Stocks
US3723032062
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 115B 17.55B 15.35B 14.16B 13.07B 24.81B 1,673B 25.23B 169B 66.42B 824B 65.88B 64.45B 2,834B | P/E 2026 * |
24.5x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 134B 20.49B 17.93B 16.53B 15.27B 28.98B 1,955B 29.46B 198B 77.58B 963B 76.95B 75.27B 3,310B | EV / Sales 2026 * |
4.79x | EV / Sales 2027 * | 3.85x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: GENB AS
| 1 day | +0.22% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.22% | +0.50% | - | - | 17.55B | |
| -4.14% | -8.06% | +57.35% | +117.24% | 54.63B | |
| +1.84% | -0.66% | +75.79% | +93.87% | 54.88B | |
| -2.24% | +3.59% | +19.60% | +466.72% | 25.06B | |
| -1.60% | -6.21% | -19.69% | -14.84% | 23.14B | |
| +2.43% | +1.06% | +47.70% | -0.11% | 19.88B | |
| -6.84% | +2.18% | +195.12% | +357.18% | 16.5B | |
| -1.05% | +1.16% | +25.08% | +196.28% | 14.2B | |
| +8.74% | +3.51% | +53.81% | - | 15.36B | |
| -4.16% | +1.63% | +70.58% | +143.85% | 12.37B | |
| Average | -0.68% | -0.10% | +58.37% | +170.02% | 26.23B | |
| Weighted average by Cap. | -0.83% | -1.40% | +57.42% | +151.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.99B 4.28B 3.74B 3.45B 3.19B 6.05B 408B 6.15B 41.26B 16.2B 201B 16.07B 15.72B 691B | 32.82B 5.02B 4.39B 4.05B 3.74B 7.1B 479B 7.22B 48.39B 19B 236B 18.85B 18.44B 811B |
| Net income | 4.74B 725M 634M 585M 540M 1.02B 69.11B 1.04B 6.99B 2.74B 34.05B 2.72B 2.66B 117B | 7.07B 1.08B 946M 873M 806M 1.53B 103B 1.56B 10.43B 4.1B 50.84B 4.06B 3.97B 175B |
| Net Debt | 19.27B 2.95B 2.58B 2.38B 2.2B 4.17B 281B 4.24B 28.42B 11.16B 139B 11.07B 10.83B 476B | 11.76B 1.8B 1.57B 1.45B 1.34B 2.54B 172B 2.59B 17.34B 6.81B 84.51B 6.75B 6.61B 291B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
